ASML Is Now the Bottleneck: Supply Falls Short Through 2028, Orders Discussed for 2029–2030

ASML Is Now the Bottleneck: Supply Falls Short Through 2028, Orders Discussed for 2029–2030

ASML's Q3 2026 (reported October 14, 2026) was a record — €11.7B total net sales and €5.0B net income (ASML press release) — but the real news was capacity: CEO Christophe Fouquet, who in April told shareholders ASML would avoid becoming the chip industry's bottleneck "by all possible means," six months later acknowledged ASML's supply of lithography tools will fall short of demand in both 2027 and 2028 (Reuters, Oct 15).

"ASML itself is now the bottleneck," said Han Dieperink, chief investment officer at Aureus, which holds the stock — management is openly acknowledging that planned 30% capacity additions in 2027 and 2028 will not be enough. Discussions about future orders are already extending into 2029 and 2030. ASML had planned to raise annual capacity to 110 of its ~$200M EUV machines by 2028 and is now looking at adding perhaps a dozen more; the new Eindhoven manufacturing phase doesn't come online until 2029. Fouquet reassured investors that ASML's own supply chain, including optics supplier Zeiss, is not the limiting factor. ASML has said it will also benefit from price increases in 2027–2028 (Reuters).

ASML is also hardening its order book: it now demands sizeable down payments that CFO Roger Dassen said are "enough to hurt" if customers later try to cancel. And it is deliberately refusing to over-book the far years: "We don't want now to accept orders from customer A, B, and C and then to tell customer D, who hasn't given orders yet for 2029 and 2030, sorry, we're sold out" — Dassen to analysts (Reuters).

The customer set confirms the AI capex chain is still tightening: TSMC maintained 2026 capex of $60–64B and says equipment supply won't constrain its expansion; Samsung, SK Hynix and Micron are all booking EUV/DUV capacity amid the AI memory shortage (The Memory Shortage: Micron's Record FQ4 2026 Extends Tightness Through 2028); Elon Musk's Terafab could emerge as a significant new buyer; China remains ~20% of sales with US restrictions a DUV risk (Reuters).

Yet the stock derated anyway — ASML shares fell 5% on Thursday in the broader AI rout, and the valuation has compressed to ~30x forward earnings from >45x in June even as analysts ratcheted up estimates¹. Jefferies' Janardan Menon: "The primary factor driving this derating is scepticism about very high 2028 and 2029 expectations," with the P/E potentially falling to the low 20s in a downturn (Reuters, The Credit Repricing: CoreWeave's Bonds Go Distressed and the AI Selloff Escapes the Neoclouds).

What it means: ASML is the cleanest read on the capex cycle's real constraint — the equipment to expand capacity is itself sold out years ahead, and customers are jockeying for 2029–2030 slots while ASML holds back over-booking. That is maximum-strength demand evidence. The market's counter-read: expectations for 2028–29 are already so high, and the financing behind customer capex so stretched, that record prints no longer clear the bar. Watch whether ASML's "sold out through 2028" stance survives any hyperscaler capex deceleration in the Oct 21–29 prints — equipment orders are the last link to break in a downturn (TSMC Q3 2026: Sixth Straight Record Quarter, 2nm at 8% of Wafers — and the Stock Falls Anyway).